title: Reduction of decoy receptor 3 enhances TRAIL-mediated apoptosis in pancreatic cancer.
abstract: Most human pancreatic cancer cells are resistant to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis. However, the mechanisms by which pancreatic cancer cells utilize their extracellular molecules to counteract the proapoptotic signaling mediated by the TNF family are largely unknown. In this study, we demonstrate for the first time that DcR3, a secreted decoy receptor that malignant pancreatic cancer cells express at a high level, acts as an extracellular antiapoptotic molecule by binding to TRAIL and counteracting its death-promoting function. The reduction of DcR3 with siRNA unmasked TRAIL and greatly enhanced TRAIL-induced apoptosis. Gemcitabine, a first-line drug for pancreatic cancer, also reduced the level of DcR3. The addition of DcR3 siRNA further enhanced gemcitabine-induced apoptosis. Notably, our in vivo study demonstrated that the therapeutic effect of gemcitabine could be enhanced via further reduction of DcR3, suggesting that downregulation of DcR3 in tumor cells could tip the balance of pancreatic cells towards apoptosis and potentially serve as a new strategy for pancreatic cancer therapy.
authors.affiliation: Department of General Surgery, Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Mei
authors.initials: M
authors.lastname: Zhang
authors.forename: Weimin
authors.initials: W
authors.lastname: Sun
authors.forename: Shanmin
authors.initials: S
authors.lastname: Yang
authors.forename: Ying
authors.initials: Y
authors.lastname: Su
authors.forename: Hengshan
authors.initials: H
authors.lastname: Zhang
authors.forename: Chaomei
authors.initials: C
authors.lastname: Liu
authors.forename: Xinfeng
authors.initials: X
authors.lastname: Li
authors.forename: Ling
authors.initials: L
authors.lastname: Lin
authors.forename: Sunghee
authors.initials: S
authors.lastname: Kim
authors.forename: Paul
authors.initials: P
authors.lastname: Okunieff
authors.forename: Zhenhuan
authors.initials: Z
authors.lastname: Zhang
authors.forename: Lurong
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics*; D045744:Cell Line, Tumor; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D004195:Disease Models, Animal; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D051379:Mice; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology; D011485:Protein Binding; D034622:RNA Interference; D053323:Receptors, Tumor Necrosis Factor, Member 6b / Q000235:genetics* / Q000378:metabolism; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism*; D047368:Tumor Burden / Q000187:drug effects / Q000235:genetics; D053326:Tumor Necrosis Factor Ligand Superfamily Member 14 / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D053323:Receptors, Tumor Necrosis Factor, Member 6b; D053221:TNF-Related Apoptosis-Inducing Ligand; D053326:Tumor Necrosis Factor Ligand Superfamily Member 14; D003841:Deoxycytidine; D000093542:Gemcitabine